Seeing Is Believing
Currently out of the existing stock ratings of Ravi Mehrotra, 14 are a BUY (100%).
Analyst Ravi Mehrotra works with a stock forecast success ratio of 95% fulfilled within 299.5 days on average.
Ravi Mehrotra’s has documented 27 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on BIIB, Biogen at 19-Mar-2015.
Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 3/4/2013. The price target of $200 was fulfilled within 56 days with a profit of $43.45 (27.75%) receiving and performance score of 4.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
340
$123.66 (57.16%)
340
4 days ago
17/34 (50%)
$123.31 (56.91%)
342
Buy
277
$60.66 (28.04%)
335
1 months 7 days ago
24/33 (72.73%)
$54.52 (24.51%)
126
Buy
311
$94.66 (43.76%)
311
1 months 9 days ago
3/8 (37.5%)
$91.79 (41.87%)
747
Buy
305
$88.66 (40.98%)
310
1 months 9 days ago
14/23 (60.87%)
$85.79 (39.14%)
228
Hold
250
$33.66 (15.56%)
276
1 months 13 days ago
3/14 (21.43%)
$30.92 (14.11%)
86
What Year was the first public recommendation made by Ravi Mehrotra?